Literature DB >> 15959843

Brain perfusion SPECT in patients with mild cognitive impairment and Alzheimer's disease: comparison of a semiquantitative and a visual evaluation.

W Staffen1, U Schönauer, H Zauner, I Spindler, A Mair, B Iglseder, G Bernroider, G Ladurner.   

Abstract

Due to the increasing importance of early recognition and differential diagnosis of dementias, cerebral perfusion scans using "single photon emission computed tomography" (SPECT) are increasingly integrated into the examination routine. The goal of this study was to check the diagnostic validity of SPECT scans of MCI- and DAT-patients, two subgroups out of 369 persons with etiologically unclear cognitive dysfunction, which underwent an assessment program for probable dementia including cognitive testing, cranial computed tomography, ultrasound, routine laboratory testing including vascular risk factors. After exclusion of patients with no or other forms of dementia we analyzed SPECT data of patients with mild cognitive impairment (MCI; n = 85) and dementia of the Alzheimer type (DAT; n = 78) in comparison with a healthy control group (n = 34).Visual assessment as well as a manual "regions of interest" (ROI) regionalization of the cortex were performed, whereby a ROI/cerebellum ratio was calculated as a semi-quantitative value. Association cortex areas were assessed regarding frontal, temporal, and parietal lobes of both hemispheres. When comparing the ratios of patients with DAT and controls, we found a statistically significant reduction of the cerebral perfusion in all measured cortex areas (p < 0.001). The comparison of patients with MCI with the selected control group also established a statistically significant difference in the cerebral perfusion for the evaluated cortex areas with the exception of the left hemispheric frontal and parietal cortex.A considerable number of the MCI patients showed an MMSE-score within the normal range, but with regard to the perfusion in the right hemispheric association cortex these patients also could be distinguished unambiguously from controls. Sensitivity levels found by visual assessment were at least as high as those found by the ROI method (pathological assessment: visual 49.4% vs. ROI 47.1% for MCI; visual 75.6% vs. ROI 73.1% for DAT). High experienced visual assessment of cerebral perfusion scans using SPECT provides an useful additional tool in diagnosis of cognitive impairment. The used semiquantitative ROI-method is nearly equivalent and does not depend on the experience of the investigator.

Entities:  

Mesh:

Year:  2005        PMID: 15959843     DOI: 10.1007/s00702-005-0321-5

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  34 in total

Review 1.  Cerebral blood flow and metabolic abnormalities in Alzheimer's disease.

Authors:  H Matsuda
Journal:  Ann Nucl Med       Date:  2001-04       Impact factor: 2.668

2.  Resting SPECT-neuropsychology correlation in very mild Alzheimer's disease.

Authors:  Flavio Nobili; Andrea Brugnolo; Piero Calvini; Francesco Copello; Caterina De Leo; Nicola Girtler; Silvia Morbelli; Arnoldo Piccardo; Paolo Vitali; Guido Rodriguez
Journal:  Clin Neurophysiol       Date:  2005-02       Impact factor: 3.708

3.  Direct comparison of spatially normalized PET and SPECT scans in Alzheimer's disease.

Authors:  Karl Herholz; Helge Schopphoff; Mathias Schmidt; Rüdiger Mielke; Wolfgang Eschner; Klemens Scheidhauer; Harald Schicha; Wolf-Dieter Heiss; Klaus Ebmeier
Journal:  J Nucl Med       Date:  2002-01       Impact factor: 10.057

4.  Accurate prediction of histologically confirmed Alzheimer's disease and the differential diagnosis of dementia: the use of NINCDS-ADRDA and DSM-III-R criteria, SPECT, X-ray CT, and Apo E4 in medial temporal lobe dementias. Oxford Project to Investigate Memory and Aging.

Authors:  K A Jobst; L P Barnetson; B J Shepstone
Journal:  Int Psychogeriatr       Date:  1998-09       Impact factor: 3.878

5.  Longitudinal evaluation of early Alzheimer's disease using brain perfusion SPECT.

Authors:  D Kogure; H Matsuda; T Ohnishi; T Asada; M Uno; T Kunihiro; S Nakano; M Takasaki
Journal:  J Nucl Med       Date:  2000-07       Impact factor: 10.057

6.  FDG PET imaging in patients with pathologically verified dementia.

Authors:  J M Hoffman; K A Welsh-Bohmer; M Hanson; B Crain; C Hulette; N Earl; R E Coleman
Journal:  J Nucl Med       Date:  2000-11       Impact factor: 10.057

7.  Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology.

Authors:  D S Knopman; S T DeKosky; J L Cummings; H Chui; J Corey-Bloom; N Relkin; G W Small; B Miller; J C Stevens
Journal:  Neurology       Date:  2001-05-08       Impact factor: 9.910

8.  Statistical parametric mapping of brain SPECT perfusion abnormalities in patients with Alzheimer's disease.

Authors:  Yi-Chung Lee; Ren-Shyan Liu; Yi-Chu Liao; Chen-Ming Sun; Po-Shan Wang; Pei-Ning Wang; Hsiu-Chih Liu
Journal:  Eur Neurol       Date:  2003       Impact factor: 1.710

Review 9.  PET studies in dementia.

Authors:  Karl Herholz
Journal:  Ann Nucl Med       Date:  2003-04       Impact factor: 2.668

10.  Single-photon emission computed tomography studies with 99mTc-hexamethylpropyleneamine oxime in dementia: effects of acute administration of L-acetylcarnitine.

Authors:  L Battistin; G Pizzolato; M Dam; C Da Col; N Perlotto; B Saitta; N Borsato; M Calvani; G Ferlin
Journal:  Eur Neurol       Date:  1989       Impact factor: 1.710

View more
  7 in total

1.  Does applying resolution recovery to normal databases confer an advantage over conventional 3D-stereotactic surface projection techniques?

Authors:  Nobuhiro Yada; Hideo Onishi; Masahiro Miyai; Kentarou Ozasa; Takashi Katsube; Keiichi Onoda; Masuo Haramoto; Yasushi Yamamoto; Shuhei Yamaguchi; Hajime Kitagaki
Journal:  Radiol Phys Technol       Date:  2017-02-04

2.  Rutin protects against cognitive deficits and brain damage in rats with chronic cerebral hypoperfusion.

Authors:  Jie Qu; Qiong Zhou; Ying Du; Wei Zhang; Miao Bai; Zhuo Zhang; Ye Xi; Zhuyi Li; Jianting Miao
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

3.  Framingham cardiovascular risk profile correlates with impaired hippocampal and cortical vasoreactivity to hypercapnia.

Authors:  Lidia Glodzik; Henry Rusinek; Miroslaw Brys; Wai H Tsui; Remigiusz Switalski; Lisa Mosconi; Rachel Mistur; Elizabeth Pirraglia; Susan de Santi; Yi Li; Alexander Goldowsky; Mony J de Leon
Journal:  J Cereb Blood Flow Metab       Date:  2010-09-15       Impact factor: 6.200

4.  Cerebral perfusion (HMPAO-SPECT) in patients with depression with cognitive impairment versus those with mild cognitive impairment and dementia of Alzheimer's type: a semiquantitative and automated evaluation.

Authors:  W Staffen; J Bergmann; U Schönauer; H Zauner; M Kronbichler; S Golaszewski; G Ladurner
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-01-10       Impact factor: 9.236

Review 5.  Is Vasomotion in Cerebral Arteries Impaired in Alzheimer's Disease?

Authors:  Luigi Yuri Di Marco; Eszter Farkas; Chris Martin; Annalena Venneri; Alejandro F Frangi
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

6.  Combining SPECT and Quantitative EEG Analysis for the Automated Differential Diagnosis of Disorders with Amnestic Symptoms.

Authors:  Yvonne Höller; Arne C Bathke; Andreas Uhl; Nicolas Strobl; Adelheid Lang; Jürgen Bergmann; Raffaele Nardone; Fabio Rossini; Harald Zauner; Margarita Kirschner; Amirhossein Jahanbekam; Eugen Trinka; Wolfgang Staffen
Journal:  Front Aging Neurosci       Date:  2017-09-07       Impact factor: 5.750

7.  Icariside II Ameliorates Cognitive Impairments Induced by Chronic Cerebral Hypoperfusion by Inhibiting the Amyloidogenic Pathway: Involvement of BDNF/TrkB/CREB Signaling and Up-Regulation of PPARα and PPARγ in Rats.

Authors:  Caixia Yin; Yuanyuan Deng; Yuangui Liu; Jianmei Gao; Lingli Yan; Qihai Gong
Journal:  Front Pharmacol       Date:  2018-10-23       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.